Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Oppenheimer Assumes ESSA Pharma at Outperform, Announces Price Target of $17

Author: Benzinga Newsdesk | June 26, 2023 06:48am
Oppenheimer analyst Mark Breidenbach assumes ESSA Pharma (NASDAQ:EPIX) with a Outperform rating and announces Price Target of $17.

Posted In: EPIX

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist